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2-[18F]-Fluoro-3-pyridinecarboxaldehyde ([18F]FPCA) is a novel, water-soluble prosthetic group. It's
radiochemistry has been developed and fully-automated for application in chemoselective radiolabelling
of amino(oxy)-derivatised RI-OR2-TAT peptide, (Aoa-k)-RI-OR2-TAT, using a GE TRACERlab FX-FN. RI-
OR2-TAT is a brain-penetrant, retro-inverso peptide that binds to amyloid species associated with Alz-
heimer's Disease. Radiolabelled (Aoa-k)-RI-OR2-TAT was reproducibly synthesised and the product of the
reaction with FPCA has been fully characterised. In-vivo biodistribution of [18F]RI-OR2-TAT has been
measured in Wistar rats.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Background
Positron emission tomography (PET) is a highly-sensitive and
quantitative molecular imaging modality, enabling non-invasive
investigation of physiological events at the molecular level. The
advent of novel radiotracers for use in PET has facilitated the
discovery of inﬂuential pathological biomarkers. Automation of
radiosynthesis aids translation from pre-clinical to clinical studies
by enhancing reproducibility and reliability. Automation is,
therefore, an important step in radiotracer development. The GE
TRACERlab FX-FN is a popular radiosynthesis platform which is
easily adaptable to automate a variety of radiosynthetic routes.
(Taylor et al., 2010; Parthsarathy et al., 2013) have reported the
development of RI-OR2 (Ac-rGffvlkGr-NH2), a retro-inverso pep-
tide comprised of D-amino acids which confers high proteolytic
stability to the peptide. RI-OR2 binds to amyloid species associated
with Alzheimer's Disease (AD) with nanomolar afﬁnity (kd¼58–
125 nM) and has been identiﬁed as an inhibitor of early-stager Ltd. This is an open access article
ster.ac.uk (O. Morris).amyloid aggregates (Parthsarathy et al., 2013). More recently, RI-
OR2 was functionalised with a retro-inverso ‘TAT’ motif to aid its
crossing the blood brain barrier (BBB), resulting in the sequence
Ac-rGffvlkGrrrrqrrkkrGy-NH2, and a molecular weight of 2860 Da
(Parthsarathy et al., 2013). ‘TAT’ is the HIV protein transduction
domain and has been reported to enhance cell-permeability and
aid transport across the BBB (Rizzuti et al., 2015). Radiolabelling of
RI-OR2-TAT would establish its usefulness as a PET radiotracer for
use in AD. In order to do this, it was ﬁrst necessary to devise a
radiosynthetic strategy to radiolabel RI-OR2 with the [18F]ﬂuorine,
a PET isotope with a appropriate radionuclide half-life (t1/2
109.8 min).
Here we report a novel, water-soluble prosthetic group, 2-[18F]
ﬂuoro-3-pyridinecarboxaldehyde ([18F]FPCA) which has been de-
veloped for use in peptide and protein radiolabelling. Its solubility
in aqueous media makes it highly suitable for radiolabelling pep-
tides and proteins, such as RI-OR2-TAT, that are sensitive to or-
ganic solvent. The half-life of 18F (t1/2 109.8 min) not only permits
multi-step syntheses but is also commensurate with the biological
half-life of peptides and many small proteins, such as RI-OR2-TAT.
[18F]FPCA was produced in a one-pot, one-step direct [18F]ﬂuor-
ination of a trimethylammonium precursor, 3-carboxaldehyde-N,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. a Reaction pathway showing the radiosynthesis of [18F]FPCA 1b Reaction pathway showing the conjugation of [18F]FPCA to N-ε-aminooxyacetyl-D-lysine (Aoa-k)
modiﬁed peptide ((Aoa-k)-RI-OR2-TAT) through oxime bond formation.
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in-house. The 18F-ﬂuorination of the precursor is depicted in
Fig. 1a.
In order to preserve the biological activity of the peptide, it was
necessary to site-speciﬁcally radiolabel RI-OR2-TAT. Therefore, the
peptide was further modiﬁed with an amino(oxy)-moiety to per-
mit chemoselective labelling with [18F]FPCA via oxime bond for-
mation (Namavari et al., 2008; Poethko et al., 2004). For this, an
additional D-lysine residue was linked to the C-terminal of the RI-
OR2-TAT sequence, to which the amino(oxy)-functionality was
added to the ε-amine group, resulting in (Aoa-k)-RI-OR2-TAT. The
radiolabelling pathway can be seen in Fig. 1b. It has been reported
that derivatisation of the C-terminal belonging to the ‘TAT’ frag-
ment does not impact its ability to mediate cellular uptake (Nori
et al., 2003).
Oximation of amino(oxy)-functionalised peptides with the al-
dehydic prosthetic group [18F]ﬂuorobenzaldehyde ([18F]FBA) has,
to date, been widely reported upon (Flavell et al., 2008; Glaser
et al., 2013; Rosik et al., 2014). However, the lipophilicity of [18F]
FBA makes radiolabeling of proteins sensitive to organic solvents
both problematic and unreliable. This prompted the development
of [18F]FPCA, on account of its enhanced hydrophilicity. Diversely
functionalised 18F-ﬂuoropyridine-based prosthetic groups have
been used for chemoselective 18F-labelling of macromolecules.
This includes [18F]FPyMe, a maleimide derivative for terminal cy-
steine conjugation, (de Bruin et al., 2005) and [18F]FPyKYNE, em-
ployed in azide-alkyne cycloaddition click chemistry (Kuhnast
et al., 2008). Pyridine-based 18F-prosthetic groups are not only
interesting in terms of the hydrophilic character but also the
electronic properties of the ring which enables facile 18F-aromatic
nucleophilic substitution.
This peptide radiolabelling strategy presented here, can be
applied to both amino(oxy)-derivatised peptides, as has been de-
scribed, as well as non-functionalised, native macromolecules via
reductive alkylation of the N-terminal amine or ε-amine group of
lysine residues (Means and Feeney, 1995; Prenant et al., 2008).
Here, we describe development of [18F]FPCA peptide radi-
olabelling with application to an (Aoa-k)-RI-OR2-TAT, process au-
tomation using a customised GE TRACERlab FX-FN together with
in-vitro investigation and pre-clinical metabolite and biodistribu-
tion analysis in Wistar rats.2. Methods
All solvents were purchased from Sigma-Aldrich and used
without further puriﬁcation. The amino(oxy)-peptide was pur-
chased from Biomatik (Ontario, Canada) in acetate salt at a purity
of 498%. [18F]Fluoride was produced onsite via the 18O(p, n)18F
nuclear reaction by 16.4 MeV proton bombardment of enriched
[18O]H2O using a GE PETtrace cyclotron (Bucks, UK). Analytical
HPLC was performed using a Shimadzu (Milton Keynes, UK) Pro-
minence system (LC-20AB solvent delivery system, SPD-20A dual
wavelength absorbance detector) controlled by Laura 3 software
(LabLogic, Shefﬁeld, UK), Laura 3 software via a CBM-20A con-
troller. HPLC eluate was measured for radioactivity using a Bioscan
(Oxford, UK) Flowcount B-FC 3100 gamma detector. All pre-clinical
PET scans were carried out using a Siemens (Oxford, UK) Inveons
PET-CT scanner. MALDI-MS was carried out using AXIMA perfor-
mance MALDI-TOF MS (Shimadzu, UK). Mass spectra were ac-
quired using a Waters SQD2 (Waters, UK) and 1H and 13C NMR
spectra were recorded on a Bruker Avance 500 MHz spectrometer
(Bruker, US) operated with TOPSPIN NMR software (version 2.0).
2.1. [18F]Potassium ﬂuoride
Cyclotron produced [18F]ﬂuoride was trapped on a Sep-Pak
QMA cartridge (Oasis, Waters, UK) then eluted with K2CO3 solution
(4 μmol, 0.4 ml) into a Reactor 1 containing 18-crown-6 (8 mg,
30 μmol) in acetonitrile (0.6 ml). The mixture was azeotropically
dried with 3 sequential additions of acetonitrile (1.6 ml total) at
temperature of 90 °C.
2.2. [18F]FPCA
To the reactor containing azeotropically dried [18F]ﬂuoride a
solution containing 3-carboxaldehyde-N,N,N-trimethylpyridine-2-
aminium bromide (2 mg, 8 μmol) in DMSO (200 μl) was added
and heated to 70 °C for 10 min [18F]FPCA was puriﬁed using
AFFINIMIP
s
(AFFINISEP, France) 2.0 ml SPE cartridges. Elution from
the SPE cartridge was achieved using methanol (3 ml) followed by
solvent evaporation at 60 °C, under vacuum for 6.5 min. The che-
mical identity of [18F]FPCA was determined by comparing its
chromatographic properties with those of the isotopically
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2.3. [18F]RI-OR2-TAT
A solution of (Aoa-k)-RI-OR2-TAT (2 mg, 740 nmol), gentisic
acid sodium salt (1 mg) anilinium chloride (2.6 mg) and citric acid
(0.02 M, 250 μl) was added to the puriﬁed and dried [18F]FPCA (pH
2.7). The reaction mixture was heated to 50 °C for 20 min and
puriﬁed using SE-HPLC (Superdex peptide 10/300 GL, PBS with 1%
ascorbic acid, 1 ml/min, 280 nm, tR 16.5 min) and analysed for
quality control purposes using a Jupiter C4 column (5 μ 300 Å
25010 mm, Phenomenex UK, Macclesﬁeld, Cheshire, UK) and
eluted using an acetonitrile gradient (10–85% over 25 min, 3 ml/
min at 280 nm, tR 13.5 min).3. Synthesis of stable compounds
3.1. 3-carboxaldehyde-N,N,N-trimethylpyridine-2-aminium bromide
The precursor was synthesised according to a procedure re-
ported in the literature (Olberg et al., 2010; Yue et al., 2014). In
short, 1.1 ml trimethylamine (1 M solution in THF, Fisher Scientiﬁc,
UK) was added dropwise to a solution containing 2-bromo-3-
pyridinecarboxaldehyde (1 mmol) in DMF. The reaction mixture
was left under stirring at 70 °C for 72 h. The white precipitate was
collected by ﬁltration, washed with Et2O (50 ml) and cold DCM
(10 ml) and dried under vacuum. The product 3-carboxaldehyde-
N,N,N-trimethylpyridine-2-aminium bromide was obtained with
80% yields. ESI-MS: [M - Br]þ¼165. 1H NMR (500 Mz, DMSO-d6):
10.32 (s, 1H, CHO), 8.86 (d, 1H, J 3.0 Hz, Ar H-6), 8.80 (d, 1H, J
7.5 Hz, Ar H-4), 8.06 (dd, 1H, J 7.5, 4.5 Hz, Ar H-5), 3.71( s, 9H,
NMe3).
13C NMR (125 Mz, DMSO-d6): 190.8 (C¼O), 151.8 (Ar C-3), 150.6
(Ar C-6), 147.2 (Ar C-4), 126.6 (Ar C-5), 124.6 (Ar C-2), 54.0 (NMe3).
3.2. [19F]RI-OR2-TAT
To a solution of (Aoa-k)-RI-OR2-TAT (2.9 mg, 1.01 μmol) and
anilinium chloride (1.3 mg, 10 μmol) in acetate buffer (500 μl, pH
4.7) was added 13 μl of a 0.1 M solution of 2-ﬂuoro-3-pyr-
idinecarboxaldehyde (Sigma Aldrich, UK) in ethanol. The mixture
was incubated at 50 °C for 4 h before being puriﬁed by SE-HPLC
(GE Superdex peptide 10/300 GL, PBS, 1 ml/min, 280 nm, tR
16.5 min). The collected fraction was loaded onto an Oasis HLB
cartridge (Waters) and the product was eluted with ethanol.
Evaporation of the solvent and drying of the product in a vacuum
desiccator yielded 1.9 mg of [19F]RI-OR2 (yield ¼64%). Labelling of
(Aoa-k)-RI-OR2-TAT was veriﬁed using MALDI-MS using the fol-
lowing procedure. The sample (1 μl) was spotted onto a MALDI
steel target plate, followed immediately by an equivalent volume
of matrix (10 mg/ml α-cyano-4-hydroxycinnamic acid in 50%
acetonitrile). [19F]RI-OR2-TAT was analysed in reﬂectron mode.
3.3. [19F]RI-OR2-TAT Thioﬂavin-T assay (ThT)
Thioﬂavin-T (ThT) assays were carried out at Lancaster Uni-
versity as previously described by (Taylor et al., 2010). In short, Aβ
peptides (25 μM) were incubated with ThT (15 μM) at 25 °C in 96-
well clear-bottom microtiter plates (NUNC). Inhibitor (RI-OR2-TAT
or [19F]RI-OR2-TAT) was added in molar ratios of 1:1, 1:2, 1:10
relative to Aβ. Plates were read every 10 min (λex 442 nm and λem
483 nm) using a BioTek Synergy plate reader (Swindon, UK) for a
total of 48 h.3.4. Pre-clinical PET analyses
All animal handling was in accordance with UK legislation
under the 1986 Animals (Scientiﬁc Procedures) Act.
3.5. Pre-clinical PET
Wistar rats (n ¼3) were anaesthetised using isoﬂurane (in-
duction 4% and maintained 1.5%) in 70% N2O and 30% O2 mixture.
44–55 MBq of [18F]RI-OR2-TAT was injected in the tail vein. All
scans were carried out using a Siemens Inveons PET-CT scanner.
The acquisition protocol parameters consisted of a preliminary CT
scan to attain attenuation correction factors followed by a 1 h PET
acquisition with time coincidence window of 3.432 ns and levels
of energy discrimination set between 350 keV and 650 keV. Ima-
ges were reconstructed and analysed as described elsewhere
(Boutin et al., 2015).4. Metabolite analysis
For metabolite analysis, Sprague-Dawley rats (n¼4) were used
and analysis carried out as described by Cawthorne et al. (Caw-
thorne et al., 2011). In short, brain, liver and blood samples were
taken 5 (n ¼2) and 20 min (n ¼2) post injection of [18F]RI-OR2-
TAT. Liver and brain were quickly removed and homogenised
(Ultra-turraxs, Sigma-Aldrich) in 2 ml of either ice-cold acetoni-
trile or PBS. After centrifugation (3 min, 9000 g, 4 °C, Thermo ALC
multispeed refrigerated centrifuge PK121R (Thermo Fisher Scien-
tiﬁc, UK)), the supernatant was separated from the pellet. For each
homogenate and supernatant, an aliquot was counted using a γ-
counter. Blood samples were centrifuged using a Thermo ALC
multispeed refrigerated centrifuge (2200 g, 5 min) and the plasma
was collected and added to either PBS or acetonitrile. Brain, liver
and plasma samples in both acetonitrile and PBS were then ana-
lysed using RP-HPLC to determine the non-polar and polar meta-
bolites respectively (Phenomenex Jupiter C4, 5 μ 300 Å
25010 mm, acetonitrile gradient from 10 to 85% over 25 min).5. Results and discussion
5.1. Radiochemistry development & automation
Fig. 2 shows the customised conﬁguration of the GE TRACERlab
FX-FN permitting [18F]FPCA radiosynthesis, subsequent peptide
labelling and product puriﬁcation.
In initial productions [18F]FPCA was puriﬁed by means of RP-
HPLC, followed by SPE concentration, Fig. 3 shows the chromato-
gram of the crude ﬂuorination reaction mixture. According to
HPLC data seen in Fig. 3, the incorporation of [18F]ﬂuoride is higher
than 85%, (n¼20) and remained reproducible. [18F]FPCA can be
seen with a retention time of 9.5 min with residual [18F]ﬂuoride
seen at 3.5 min
Replacement of RP-HPLC puriﬁcation with a SPE method was
implemented in the interest of time reduction but also to simplify
automation and improve reproducibility. Due to the polar nature
of the prosthetic group, it was not suitable for use with RP-SPE
cartridges and use of a hydrophobic-lipophilic balance (HLB) car-
tridge resulted in unwanted water content in the eluted fraction of
[18F]FPCA. Subsequent evaporation of elution solvent proved very
difﬁcult and problematic for automation, owing to varying vo-
lumes between productions. The variable volumes of co-eluted
water meant that evaporation times and aqueous methanol vo-
lumes were inconsistent between reactions. As a result, a vigorous
drying step was required which caused a signiﬁcant loss in
Fig. 2. Schematic of customised GE TRACERlab FX-FN conﬁguration permitting [18F]FPCA radiosynthesis, puriﬁcation and isolation followed by (Aoa-k)-RI-OR2-TAT peptide
radiolabelling and puriﬁcation.
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conditions, excess water remaining after incomplete evaporation
acted to dilute the peptide labelling reaction mixture and, again,
resulted in lower radiochemical yields.
For this reason, the AFFINIMIPs SPE 18F-Aromatic Nucleophilic
Substitution 2.0 ml cartridge was assessed and found to achieve
both good retention and resolution of [18F]FPCA from the tri-
methylammonium precursor. AFFINIMIPs SPE 18F-AromaticFig. 3. TRACERlab FX-FN radio-chromatogram trace showing crude [18F]ﬂuorination mix
and UV detector (AU) traces.Nucleophilic Substitution 2.0 ml cartridges comprise a molecular
imprinted polymer that has been validated for use with the
radiotracers [18F]ﬂuorobenzaldehyde (FBA) and [18F]ethyl-4-ﬂuor-
obenzoate. The prosthetic groups are produced from an aromatic
nucleophilic substitution with the corresponding ammonium-
based precursor. Good separation of the 18F-prosthetic groups,
from the ammonium precursor as well as the phenol- and dia-
lkylamino-based impurities, is achieved using the cartridge. Theture of [18F]FPCA (220 nm). The top and bottom spectra show the gamma (counts)
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[18F]FPCA was veriﬁed using RP-HPLC (data not shown). Reactor
1 was cleaned by addition of ethanol (2 ml) from Vial 5 before re-
addition of [18F]FPCA from the SPE cartridge for subsequent con-
jugation to (Aoa-k)-RI-OR2-TAT. This ensured that impurities from
the ﬂuorination of FPCA, that could impair peptide radiolabelling,
were minimised.
An AFFINIMIPs SPE 18F-Aromatic Nucleophilic Substitution
0.7 ml cartridge was additionally assessed in the application of
[18F]FPCA puriﬁcation. It was found that elution from the 0.7 ml
cartridge was more efﬁcient and RCYof [18F]FPCA increased to 43%,
however resolution from the precursor was poor which rendered
the cartridge unsuitable in this application. The loss in RCY of [18F]
FPCA using a 2.0 ml AFFINIMIPs cartridge was preferable owing to
the high chemical purity that was achieved.
Despite high yields of [18F]FPCA, as observed in Fig. 3, RCY of
2872%, (decay corrected, n¼10) were obtained attributable to
loss during SPE puriﬁcation and solvent evaporation steps. How-
ever, the AFFINIMIPs SPE 18F-Aromatic Nucleophilic Substitution
cartridge has not been produced speciﬁcally for in FPCA puriﬁca-
tion resulting in low recovery of [18F]FPCA. This would be mark-
edly improved by using a bespoke FPCA speciﬁc molecular im-
printed polymer cartridge.
Despite the loss of [18F]FPCA owing to puriﬁcation and solvent
evaporation, [18F]FPCA presents as an alternative water-soluble
[18F]F prosthetic group for use with peptides and proteins that are
sensitive to organic solvents.
Fig. 4 shows the SE-HPLC radio-chromatogram of the crude
[18F]RI-OR2-TAT radiolabelling mixture. SE-HPLC was used to both
purify and formulate the ﬁnal radiolabelled peptide product
through use of PBS eluent. The radiolabelling efﬁciency of the
peptide with [18F]FPCA achieved 22.573% and, based on 5 synth-
eses, was reproducible. [18F]RI-OR2-TAT and [18F]FPCA can be seen
with a retention times of 16.5 min and at 27 min respectively. A
negative UV peak is observed for both the unlabelled (Aoa-k)-RI-
OR2-TAT and FPCA precursor attributable to the high absorbance
density of the ascorbate-containing mobile phase. RP-SPE car-
tridges were also assessed for their suitability in purifying [18F]RI-
OR2-TAT. The radiolabelled peptide was strongly retained andFig. 4. TRACERlab FX-FN radio-chromatogram trace showrequired a large volume of organic eluent, additionally co-elution
of more lipophilic components and unreacted [18F]FPCA was ob-
served resulting in sub-standard radiochemical purity. Further-
more, [18F]FPCA radiosynthesis was developed and automated
with a view to radiolabelling further peptides and proteins, in this
regard SE-HPLC serves as a method by which larger or organic-
sensitive proteins can be puriﬁed and formulated.
RP-HPLC was used to assess the RCP of the ﬁnal formulated
[18F]RI-OR2-TAT product for quality control purposes. The UV-
radiochromatogram can be seen in the Supplementary Material
(Figure. a). The Figure shows a large initial peak attributable to
ascorbate and two peaks at 12.75 and 13.5 min, identiﬁed as (Aoa-
k)-RI-OR2-TAT and [18/19F]RI-OR2-TAT respectively with a RCP
490%.
The overall [18F]RI-OR2-TAT RCY achieved using the automated
platform was 1272% within 2 h from end of bombardment,
starting from 25 to 30 GBq of [18F]ﬂuoride (decay corrected, n¼5).
The speciﬁc activity of [18F]RI-OR2-TAT was calculated to be
3.271.3 GBq/μmol (at end of synthesis).
Despite the appreciable radiolabelling efﬁciencies of [18F]FPCA
and [18F]RI-OR2-TAT, the overall yield using the fully-automated
platform was lower than expected and largely attributable to
suboptimal elution of [18F]FPCA from the AFFINIMIPs SPE car-
tridge. Overall radiolabelling yields using a semi-automated
synthesis, used during early developmental stages, achieved
2075% (decay corrected, n¼5) starting with 100 MBq of [18F]
FPCA. In which, [18F]FPCA synthesis and SPE puriﬁcation was
achieved using the automated platform and [18F]FPCA evaporation
and peptide radiolabelling was completed manually (data not
shown).
Fig. 5 shows the MALDI-MS analysis of [19F]RI-OR2-TAT peptide.
The 19F-labelled peptide can be seen at 2969 m/z (MþH)þ . The
results of the MALDI-MS conﬁrm labelling of (Aoa-k)-RI-OR2-TAT
with FPCA.
5.2. Application of radiochemistry to RI-OR2-TAT
5.2.1. ThT assay
A ThT assay was used in the original publications to assess theing SE-HPLC radio-chromatogram of [18F]RI-OR2-TAT.
Fig. 5. MALDI-MS analysis of (Aoa-k)-RI-OR2-TAT peptide labelled with isotopically unchanged FPCA ([19F]FPCA). [19F]RI-OR2-TAT is shown at 2969 m/z (MþH)þ .
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aggregation (Parthsarathy et al., 2013; Taylor et al., 2010). ThT has
afﬁnity for amyloid plaque, but not for unaggregated amyloid
species, therefore the ﬂuorescent intensity of a ThT corresponds to
the degree of amyloid aggregation. Although the ThT assay does
not provide evidence for speciﬁc vs non-speciﬁc binding of the RI-
OR2-TAT analogues, it does conﬁrm their reactivity towards amy-
loid species and permits a direct comparison of RI-OR2-TAT and
[19F]RI-OR2-TAT. Results of the ThT assay can be used to verify that
the radiolabelling method has not modiﬁed the characteristics of
the peptide.
The results of the ThT assay can be seen in Fig. 6. The data
indicate the percentage inhibition of amyloid aggregation in the
presence of RI-OR2-TAT or cold labelled [19F]RI-OR2-TAT, shown in
blue and red respectively, at different inhibitor: Aβ molar ratios.
Aβ aggregation, in the absence of inhibitor, can be seen in grey.
The chart shows that the inhibition efﬁciency of [19F]RI-OR2-TAT is
reduced 3-fold at an inhibitor: Aβ molar ratio of 1:2. Although the
ability of the modiﬁed peptide is lowered, this assay suggests [19F]
RI-OR2-TAT still binds, demonstrating the potential of the 18F-
analogue as a PET tracer.
5.2.2. Pre-clinical results
In-vivo biodistribution of [18F]RI-OR2-TAT was performed in
Wistar rats and results of which can be seen in Fig. 7 and Table 1.
Overall, the highest uptake was observed in liver, with a rapid
uptake reaching a plateau within 10 min post-injection, followed
by bladder (urine), kidneys, spleen, bone marrow, lungs, bone andFig. 6. Results of the Thioﬂavin-T assay (ThT) showing percentage inhibition of
amyloid aggregation in presence of either [19F]RI-OR2-TAT (red) or non-functio-
nalised RI-OR2-TAT (blue). Amyloid aggregation in the absence of inhibitor (RI-
OR2-TAT) is shown in grey. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)brain (Figs. 7 and 8). Some uptake could be observed in bone
marrow but was distinctively higher than the low uptake observed
in bone (3.18870.912 SUV and 0.38070.237 SUV respectively
60 min post-injection) (Figs. 7D and 8B). Our measures by γ-
counting of liver and brain samples were in good agreement with
our PET quantiﬁcation (Table 1). The nature of the retro-inverso
peptide is such that hepatobiliary clearance is a main route of
excretion instead of renal excretion as is often observed with small
peptides. The high proteolytic stability of peptide owes to the
absence of blood proteases able to recognise its D-amino acid
peptide bonds. It is hypothesised that the peptide accumulates in
the liver before being excreted through the intestinal tract via the
bile.
Deﬂuorination is a key metabolic process that will limit the
utility of any 18F-labelled radiotracer and is detected when accu-
mulation of radioactivity is observed within the bone. However
Figs. 7 and 8 show relatively little bone uptake thereby demon-
strating stability of [18F]FPCA to deﬂuorination. An evaluation of
[18F]ﬂuoropyridines by (Dolle, 2007) remarks upon the metabolic
resistance of the 18F-ﬂuoride radiolabel in the ortho-position of
pyridine-based radiotracers.
Fig. 8A and C show the distribution of [18F]RI-OR2-TAT in rat
brain. As can be seen, the brain pharmacokinetic follows a rapid
peak (within 30 s post-injection) of uptake of [18F]RI-OR2-TAT
corresponding to the ﬁrst pass of the peptide with the blood ﬂow
followed by a rapid washout (Fig. 8C). After 10 min, very little
brain retention of [18F]RI-OR2-TAT is observed. This was as ex-
pected due to absence of AD pathology in the brains of Wistar rats.
The speciﬁc activity of the [18F]RI-OR2-TAT is currently low,
however RI-OR2-TAT binds to Aβ plaques but also to Aβ oligomers.
Binding to such a complex is not readily saturable, as is expected
with receptor-based binding (i.e. there is no 1–1 stoichiometry but
multiple binding sites per plaques or oligomers). Consequently, it
is important to qualify that the speciﬁc activity of [18F]RI-OR2-TAT
does not contribute to poor brain signal. Despite the presence of
multiple binding sites, transportation of [18F]RI-OR2 across the
BBB maybe hindered by competition of [18F]RI-OR2-TAT with un-
labelled (Aoa-k)-RI-OR2-TAT. Therefore, an improvement in spe-
ciﬁc activity by separation of labelled and unlabelled peptide
would safeguard against issues of radiotracer concentration af-
fecting its pre-clinical performance.
Table 2 shows the analysis of the polar and non-polar fractions
in the brain, liver and plasma samples collected in PBS and acet-
onitrile portions respectively at 5 and 20 min post-injection. In
liver and plasma, the radioactivity detected is almost exclusively a
polar species that has been identiﬁed using RP-HPLC as parent
[18F]RI-OR2-TAT; no other radiolabelled component was identiﬁed
using RP-HPLC (Supplementary Figure. b). In the brain, some non-
Fig. 7. Representative sum images (20–60 min) of a Wistar rat after injection of [18F]RI-OR2-TAT. Time activity curves in bladder, kidneys, and spleen are from 1 animal. Data
for bone marrow and liver are expressed as SUV (mean7SD of 3 rats).
Table 1
Biodistribution by γ-counting of [18F]RI-OR2-TAT in brain, liver, whole-blood and
plasma, and plasma to blood ratio 5 and 20 min post-injection (n¼2 per time-
point, data expressed as SUV, mean7SD).
Polar





Plasma/blood ratio 1.4770.01 1.7470.23
O. Morris et al. / Applied Radiation and Isotopes 116 (2016) 120–127126polar species were detected in higher proportions than in the
plasma or liver. This suggests the presence more lipophilic com-
pounds which traverse the BBB more easily. Considering the ex-
tremely low level of radioactivity detected in the brain
(0.01770.002 SUV 60 min post-injection), further evaluation is
needed to deduce the impact of such compounds on the signal to
noise ratio in models of AD with detectable β-amyloid. The results
of this analysis, however, conﬁrm the in-vivo stability of both the
peptide and the [18F]FPCA radiolabel.6. Conclusion
We report the radiosynthesis of a novel, water-soluble pros-
thetic group, [18F]FPCA, and its automation using a GE TRACERlab
FX-FN. [18F]Fluoride radiolabelling efﬁciency of [18F]FPCA achieved
yields 485% (n¼20). Puriﬁed and dried [18F]FPCA was obtained
within 45 min from end of bombardment with RCP of approx. 95%
and RCY of 28%72 (decay-corrected, n¼10). Overall RCYs of the
[18F]RI-OR2-TAT achieved were 1272% within 2 h, starting from
25 to 30 GBq of [18F]ﬂuoride (decay corrected, n¼5).The pre-clinical study of [18F]RI-OR2-TAT demonstrates in-vivo
stability of the tracer and primarily hepatobiliary excretion of the
intact peptide owing to its retro-inverso amino-acid sequence.
Very low brain penetration was observed conceivably resulting
from the low speciﬁc activity. Further work is in progress to im-
prove the speciﬁc activity, by means of separation of the labelled
and unlabelled peptide, and assess the tracer in animal models of
AD.
Development and automation of [18F]FPCA radiochemistry has
produced reproducible radiolabelling of (Aoa-k)-RI-OR2-TAT. This
presents [18F]FPCA radiochemistry and automation as a useful and
generic 18F-prosthetic group for use in peptide and protein radi-
olabelling via both oxime-bond formation, as has been described
in this article, or reductive alkylation.Competing interests
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Fig. 8. Representative sum images 20–60 min post-injection (insert: 13–22 s post-injection) of [18F]RI-OR2-TAT uptake in brain, bone and lungs (mean7SD, n¼2 for brain,
n¼3 for bone and lungs).
Table 2
Analysis of polar (PBS) and non-polar fractions (ACN) of [18F]RI-OR2-TAT taken
from brain, liver and plasma 5 and 20 min post-injection (n¼2 per time-point, data
expressed as mean7SD).
Polar Non-polar
5 min 20 min 5 min 20 min
Brain 7773% 6671% 2373% 3471%
Liver 9772% 9473% 372% 673%
Plasma 9674% 76710% 474% 24710%
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Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.apradiso.2016.07.
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